Literature DB >> 10807747

In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene.

N Elias1, B W Patterson, G Schonfeld.   

Abstract

Familial hypobetalipoproteinemia (FHBL) is an autosomal codominant disorder that may result from different mutations in the apolipoprotein B (apoB) gene or chromosome 2. However, linkage of FHBL to the apoB gene was ruled out in 2 kindreds reported to date, and the genetic and metabolic bases for FHBL remain unknown. One of the reported kindreds is our 40-member F kindred, in which we found linkage of FHBL to a novel susceptibility region on chromosome 3p21. 1-2. In addition to having low apoB levels, some, but not all, of the affected subjects in the F kindred also had low levels of high density lipoprotein (HDL) cholesterol and apoA-I. Our aim was to define the metabolic bases of the disorder in the F kindred. Therefore, we studied the in vivo kinetics of apoB and apoA-I and very low density lipoprotein (VLDL) triglycerides in 4 affected subjects and 5 normolipidemic relatives. Deuterated leucine and deuterated glycerol were used to label the apolipoproteins and triglycerides, respectively. Compartmental modeling was used to obtain the kinetic parameters. Affected subjects had (1) normal fractional catabolic rates (FCRs) for VLDL apoB, (2) increased FCRs for low density lipoprotein (LDL) apoB (0.050+/-0.009 versus 0. 030+/-0.006 pools per hour for normal subjects, P=0.005), and (3) decreased production rates of VLDL apoB (11.4+/-1.7 versus 25.6+/-4. 9 mg. kg(-1). d(-1), P=0.003), LDL apoB (7.8+/-1.3 versus 12.7+/-3.7 mg. kg(-1). d(-1), P=0.04), and VLDL triglycerides (8.2+/-4.5 versus 19.6+/-10.8 58 micromol. kg(-1). h(-1), P=0.09). These data differ from those obtained in previously studied FHBL heterozygotes bearing apoB-2 and apoB-9, 2 very short truncations of apoB. Low HDL cholesterol and apoA-I levels were caused by higher apoA-I FCRs (0. 035+/-0.005 versus 0.018+/-0.005 pools per hour in controls, P<0.01) without significant decrease in apoA-I production rates (18.7+/-2.7 versus 22.8+/-5.6 mg. kg(-1). d(-1)). In conclusion, decreased secretion of apoB-containing lipoproteins and hypercatabolism of LDL account for low apoB and cholesterol levels in this novel form of FHBL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807747     DOI: 10.1161/01.atv.20.5.1309

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  12 in total

1.  Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.

Authors:  Sergio Fazio; Jessica Minnier; Michael D Shapiro; Sotirios Tsimikas; Patrizia Tarugi; Maurizio R Averna; Marcello Arca; Hagai Tavori
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

Review 2.  Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments.

Authors:  Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2006-09-01       Impact factor: 5.922

3.  Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.

Authors:  Randall J Bateman; Ling Y Munsell; John C Morris; Robert Swarm; Kevin E Yarasheski; David M Holtzman
Journal:  Nat Med       Date:  2006-06-25       Impact factor: 53.440

4.  Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis.

Authors:  Ilenia Minicocci; Sara Santini; Vito Cantisani; Nathan Stitziel; Sekar Kathiresan; Juan Antonio Arroyo; Gertrudis Martí; Livia Pisciotta; Davide Noto; Angelo B Cefalù; Marianna Maranghi; Giancarlo Labbadia; Giovanni Pigna; Fabio Pannozzo; Fabrizio Ceci; Ester Ciociola; Stefano Bertolini; Sebastiano Calandra; Patrizia Tarugi; Maurizio Averna; Marcello Arca
Journal:  J Lipid Res       Date:  2013-09-20       Impact factor: 5.922

5.  Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates.

Authors:  Randall J Bateman; Ling Y Munsell; Xianghong Chen; David M Holtzman; Kevin E Yarasheski
Journal:  J Am Soc Mass Spectrom       Date:  2007-02-22       Impact factor: 3.109

6.  Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization.

Authors:  Ilenia Minicocci; Anna Montali; Marius Robert Robciuc; Fabiana Quagliarini; Vincenzo Censi; Giancarlo Labbadia; Claudia Gabiati; Giovanni Pigna; Maria Laura Sepe; Fabio Pannozzo; Dieter Lütjohann; Sergio Fazio; Matti Jauhiainen; Christian Ehnholm; Marcello Arca
Journal:  J Clin Endocrinol Metab       Date:  2012-06-01       Impact factor: 5.958

7.  Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia.

Authors:  Kiran Musunuru; James P Pirruccello; Ron Do; Gina M Peloso; Candace Guiducci; Carrie Sougnez; Kiran V Garimella; Sheila Fisher; Justin Abreu; Andrew J Barry; Tim Fennell; Eric Banks; Lauren Ambrogio; Kristian Cibulskis; Andrew Kernytsky; Elena Gonzalez; Nicholas Rudzicz; James C Engert; Mark A DePristo; Mark J Daly; Jonathan C Cohen; Helen H Hobbs; David Altshuler; Gustav Schonfeld; Stacey B Gabriel; Pin Yue; Sekar Kathiresan
Journal:  N Engl J Med       Date:  2010-10-13       Impact factor: 91.245

8.  Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.

Authors:  Maartje E Visser; Fatima Akdim; Diane L Tribble; Aart J Nederveen; T Jesse Kwoh; John J P Kastelein; Mieke D Trip; Erik S G Stroes
Journal:  J Lipid Res       Date:  2009-12-14       Impact factor: 5.922

9.  In vivo human apolipoprotein E isoform fractional turnover rates in the CNS.

Authors:  Kristin R Wildsmith; Jacob M Basak; Bruce W Patterson; Yuriy Pyatkivskyy; Jungsu Kim; Kevin E Yarasheski; Jennifer X Wang; Kwasi G Mawuenyega; Hong Jiang; Maia Parsadanian; Hyejin Yoon; Tom Kasten; Wendy C Sigurdson; Chengjie Xiong; Alison Goate; David M Holtzman; Randall J Bateman
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

10.  Familial hypobetalipoproteinemia-induced nonalcoholic steatohepatitis.

Authors:  Mindy C W Lam; Janakie Singham; Robert A Hegele; Maziar Riazy; Matti A Hiob; Gordon Francis; Urs P Steinbrecher
Journal:  Case Rep Gastroenterol       Date:  2012-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.